NEWARK,
Del., June 26, 2024 /PRNewswire/ -- bioSeedin, a
flourishing global licensing and consulting platform, captivated
attendees as an esteemed exhibitor at the BIO International
Convention, the preeminent global biotech gathering. This
prestigious event unfolded in San
Diego, spanning from June 3rd to June
6th, 2024, over the course of four enlightening days.
At the distinguished four-day event, the seasoned Business
Development (BD) teams of bioSeedin, hailing from the United States, were at the forefront of
dynamic and fruitful dialogues with prospective partners and
industry influencers from around the globe. These profound
exchanges encompassed pharmaceutical entities from the United States, Europe, Japan, Korea, Australia, and other pivotal markets.
The discussions were anchored by bioSeedin's extensive portfolio
of over 60 featured assets, showcasing a spectrum of therapeutic
innovations. These included small molecules, protein drugs,
Antibody-Drug Conjugates (ADCs) and Peptide-Drug Conjugates (PDCs),
as well as Cell and Gene Therapies (CGT). The breadth of
bioSeedin's offerings addresses a multitude of medical conditions,
ranging from neurological and metabolic disorders to oncological,
respiratory, cardiovascular, and immunological diseases, reflecting
the company's commitment to advancing healthcare solutions across a
wide array of therapeutic areas.
With great enthusiasm, bioSeedin proudly declares that amidst
the vibrant atmosphere of this conference, a milestone has been
achieved through the establishment of a strategic cooperation
agreement with the esteemed Korean AI company Syntekabio. This
alliance marks a significant step forward in fostering
collaborative growth and innovation within the biotech landscape,
promising a synergistic future that will be defined by mutual
advancement and shared success.
As Jenny Zhao, the CEO of
bioSeedin, pointed out, "I am proud of the work we have done and
excited about the future opportunities. With a robust network of
over 9,000 biotechnology and pharmaceutical companies spanning over
70 countries, our vast experience in managing global assets, and
our top-notch BD team, we are equipped to provide the necessary
guidance and support to the complex market. Let us continue to
leverage our strengths, stay ahead of market trends, and help our
clients achieve their goals. Together, we will continue to lead the
global pharmaceutical industry."
About bioSeedin
bioSeedin is a global transaction and consultation platform that
specializes in therapeutic asset management and public relations
services. The company offers a comprehensive range of services,
including licensing in and out, co-developmental partner sourcing,
project implementation, public relation management advisory,
emerging market entry strategies, investment strategies, mergers
and acquisitions, and capital raising. By facilitating increased
R&D efficiency, optimizing research resources and funding, and
providing access to emerging markets, bioSeedin is committed to
accelerating the delivery of therapeutics worldwide, ultimately
benefiting patients on a global scale. Visit at
www.bioseedin.com
View original
content:https://www.prnewswire.com/news-releases/bioseedin-expanded-global-licensing-and-partnership-opportunities-at-2024-bio-international-convention-302182611.html
SOURCE bioSeedin